Upsher-Smith Laboratories LLC, a subsidiary of Bora Pharmaceuticals Co Ltd (TW:6472 and OTCQX:BORAY), announced on Wednesday that it has launched its Cyclosporine Ophthalmic Emulsion 0.05%, therapeutically equivalent to the Reference Listed Drug (RLD), RESTASIS (cyclosporine ophthalmic emulsion) 0.05%.
Cyclosporine ophthalmic emulsion is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca.
According to IQVIA, the US market for cyclosporine ophthalmic emulsion generated sales of approximately USD1.9bn in the 12 months from February 2025 to January 2026.
Bora received US Food and Drug Administration (FDA) approval of its abbreviated new drug application (ANDA) for the product in January 2026.
Whitehawk Therapeutics signs new option agreement for use of CPT113 linker-payload
Hims & Hers expands GLP-1 offering in Canada with generic semaglutide
Bayer's KERENDIA receives FDA priority review for type 1 diabetes and kidney disease treatment
Upsher-Smith launches generic Cyclosporine Ophthalmic Emulsion 0.05%
Hyundai Bioscience says XAFTY available for Ebola and Hantavirus treatment
4basebio secures clinical supply agreement for Phase II immunotherapy trial
FDA approves MEKanistic Therapeutics' IND for MTX-531
Matter Bio submits first IND application for Lm-LLO-TT
Myosin Therapeutics doses first patient in Phase 1/2 study of MT-125 in GBM
Accro Bioscience completes USD50m Series C financing
Dexcom launches Dexcom Flex CGM system for Type 2 diabetes patients in Germany
ImmunityBio secures US patent portfolio covering ANKTIVA combination therapy through to 2035
Artivion completes acquisition of Endospan following FDA approval of NEXUS Aortic Arch System
AstraZeneca wins US approval for Baxfendy as first aldosterone synthase inhibitor for hypertension